3 Days
Source:
The Boston Globe
_1777370193195_831968492.png&w=48&q=75){kind=small}
New drug offers hope for pancreatic cancer patients
A new experimental drug called daraxonrasib has shown promising results in treating advanced pancreatic cancer. Developed to target the KRAS mutation prevalent in the disease, the medication has extended patients’ survival times significantly in clinical trials. As it awaits FDA approval, some patients, including Lazar Mandinov, are receiving the drug outside of trials through expanded access programs, offering hope for improved outcomes in a cancer that is typically considered highly lethal.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)